Amylyx Pharmaceuticals Inc (AMLX)

$5.27 +0.22 (4.36%)
Market Cap 438.57M
Revenue (ttm) 87.37M
Net Income (ttm) -301.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -345.36%
Debt to Equity Ratio 0.00
Volume 423,280
Avg Vol 938,096
Day's Range N/A - N/A
Shares Out 89.14M
Stochastic %K 54%
Beta -0.59
Analysts Strong Sell
Price Target $11.00

Latest News on AMLX

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 5, 2025, 10:00 AM EDT - 1 day ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation

Jun 3, 2025, 10:00 AM EDT - 3 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Jun 3, 2025, 7:00 AM EDT - 3 days ago

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect

Jun 1, 2025, 10:00 AM EDT - 5 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

May 29, 2025, 10:05 AM EDT - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation

May 27, 2025, 10:00 AM EDT - 10 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 12 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 15 days ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 21, 2025, 7:00 AM EDT - 16 days ago

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

May 18, 2025, 10:00 AM EDT - 19 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

May 15, 2025, 10:00 AM EDT - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

May 13, 2025, 10:00 AM EDT - 24 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

May 12, 2025, 7:00 AM EDT - 25 days ago

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out

May 11, 2025, 10:00 AM EDT - 26 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call Transcript

May 10, 2025, 11:19 AM EDT - 27 days ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call Transcript

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect

May 8, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 4 weeks ago

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

May 7, 2025, 8:00 AM EDT - 4 weeks ago

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out

May 4, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation

May 1, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation

Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

May 1, 2025, 9:00 AM EDT - 5 weeks ago

Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

Apr 30, 2025, 7:00 AM EDT - 5 weeks ago

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 13, 2025, 10:00 AM EDT - 7 weeks ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

Apr 9, 2025, 7:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 9:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 12:02 PM EST - 3 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2024 Earnings Call Transcript

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 4, 2025, 6:00 AM EST - 3 months ago

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Feb 25, 2025, 9:00 AM EST - 3 months ago

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Feb 24, 2025, 9:00 AM EST - 3 months ago

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 9:00 AM EST - 4 months ago

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Jan 21, 2025, 9:00 AM EST - 4 months ago

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Jan 10, 2025, 8:26 AM EST - 5 months ago

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Jan 9, 2025, 7:30 PM EST - 5 months ago

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

Jan 6, 2025, 9:00 AM EST - 5 months ago

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

Dec 4, 2024, 7:30 AM EST - 6 months ago

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 27, 2024, 9:00 AM EST - 6 months ago

Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

Nov 25, 2024, 2:40 PM EST - 6 months ago

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 10:06 AM EST - 7 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 7:00 AM EST - 7 months ago

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Nov 4, 2024, 9:00 AM EST - 7 months ago

Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Oct 17, 2024, 9:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Oct 15, 2024, 9:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 28, 2024, 8:30 AM EDT - 10 months ago

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration

Aug 12, 2024, 9:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 9:02 AM EDT - 10 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript

Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 7:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Aug 5, 2024, 9:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome

Aug 2, 2024, 9:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome

Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?

Jul 10, 2024, 3:32 PM EDT - 11 months ago

Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?